

Infection fatality rate of COVID-19 inferred from seroprevalence data

John P A Ioannidis^a

Objective To estimate the infection fatality rate of coronavirus disease 2019 (COVID-19) from seroprevalence data.

Methods I searched PubMed and preprint servers for COVID-19 seroprevalence studies with a sample size ≥ 500 as of 9 September 2020. I also retrieved additional results of national studies from preliminary press releases and reports. I assessed the studies for design features and seroprevalence estimates. I estimated the infection fatality rate for each study by dividing the cumulative number of COVID-19 deaths by the number of people estimated to be infected in each region. I corrected for the number of immunoglobulin (Ig) types tested (IgG, IgM, IgA).

Findings I included 61 studies (74 estimates) and eight preliminary national estimates. Seroprevalence estimates ranged from 0.02% to 53.40%. Infection fatality rates ranged from 0.00% to 1.63%, corrected values from 0.00% to 1.54%. Across 51 locations, the median COVID-19 infection fatality rate was 0.27% (corrected 0.23%): the rate was 0.09% in locations with COVID-19 population mortality rates less than the global average (< 118 deaths/million), 0.20% in locations with 118–500 COVID-19 deaths/million people and 0.57% in locations with > 500 COVID-19 deaths/million people. In people younger than 70 years, infection fatality rates ranged from 0.00% to 0.31% with crude and corrected medians of 0.05%.

Conclusion The infection fatality rate of COVID-19 can vary substantially across different locations and this may reflect differences in population age structure and case-mix of infected and deceased patients and other factors. The inferred infection fatality rates tended to be much lower than estimates made earlier in the pandemic.

Abstracts in [عربي](#), [中文](#), [Français](#), [Русский](#) and [Español](#) at the end of each article.

Introduction

The infection fatality rate, the probability of dying for a person who is infected, is one of the most important features of the coronavirus disease 2019 (COVID-19) pandemic. The expected total mortality burden of COVID-19 is directly related to the infection fatality rate. Moreover, justification for various non-pharmacological public health interventions depends on the infection fatality rate. Some stringent interventions that potentially also result in more noticeable collateral harms¹ may be considered appropriate, if the infection fatality rate is high. Conversely, the same measures may fall short of acceptable risk–benefit thresholds, if the infection fatality rate is low.

Early data from China suggested a 3.4% case fatality rate² and that asymptomatic infections were uncommon,³ thus the case fatality rate and infection fatality rate would be about the same. Mathematical models have suggested that 40–81% of the world population could be infected,^{4,5} and have lowered the infection fatality rate to 1.0% or 0.9%.^{5,6} Since March 2020, many studies have estimated the spread of the virus causing COVID-19 – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – in various locations by evaluating seroprevalence. I used the prevalence data from these studies to infer estimates of the COVID-19 infection fatality rate.

Methods

Seroprevalence studies

The input data for calculations of infection fatality rate were studies on the seroprevalence of COVID-19 done in the general population, or in samples that might approximately represent the general population (e.g. with proper reweighting), that had been published in peer-reviewed journals or as preprints (irrespective of language) as of 9 September 2020. I considered only studies with at least 500 assessed samples

because smaller data sets would result in large uncertainty for any calculations based on these data. I included studies that made seroprevalence assessments at different time intervals if at least one time interval assessment had a sample size of at least 500 participants. If there were different eligible time intervals, I selected the one with the highest seroprevalence, since seroprevalence may decrease over time as antibody titres decrease. I excluded studies with data collected for more than a month that could not be broken into at least one eligible time interval less than one month duration because it would not be possible to estimate a point seroprevalence reliably. Studies were eligible regardless of the exact age range of participants included, but I excluded studies with only children.

I also examined results from national studies from preliminary press releases and reports whenever a country had no other data presented in published papers or preprints. This inclusion allowed these countries to be represented, but information was less complete than information in published papers or preprints and thus requires caution.

I included studies on blood donors, although they may underestimate seroprevalence and overestimate infection fatality rate because of the healthy volunteer effect. I excluded studies on health-care workers, since this group is at a potentially high exposure risk, which may result in seroprevalence estimates much higher than the general population and thus an improbably low infection fatality rate. Similarly, I also excluded studies on communities (e.g. shelters or religious or other shared-living communities). Studies were eligible regardless of whether they aimed to evaluate seroprevalence in large or small regions, provided that the population of reference in the region was at least 5000 people.

I searched PubMed^{*} (LitCOVID), and medRxiv, bioRxiv and Research Square using the terms “seroprevalence” OR “antibodies” with continuous updates. I made the first search in early May and did monthly updates, with the last update

^a Meta-Research Innovation Center at Stanford (METRICS), Stanford University, 1265 Welch Road, Stanford, California 94305, United States of America.

Correspondence to John P A Ioannidis (email: jioannid@stanford.edu).

(Submitted: 13 May 2020 – Revised version received: 13 September 2020 – Accepted: 15 September 2020 – Published online: 14 October 2020)

on 9 September 2020. I contacted field experts to retrieve any important studies that may have been missed.

From each study, I extracted information on location, recruitment and sampling strategy, dates of sample collection, sample size, types of antibody measured (immunoglobulin G (IgG), IgM and IgA), the estimated crude seroprevalence (positive samples divided by all samples tested), adjusted seroprevalence and the factors that the authors considered for adjustment.

Inferred infection fatality rate

If a study did not cover an entire country, I collected information on the population of the relevant location from the paper or recent census data so as to approximate as much as possible the relevant catchment area (e.g. region(s) or county(ies)). Some studies targeted specific age groups (e.g. excluding elderly people and/or excluding children) and some estimated numbers of people infected in the population based on specific age groups. For consistency, I used the entire population (all ages) and, separately, the population 0–70 years to estimate numbers of infected people. I assumed that the seroprevalence would be similar in different age groups, but I also recorded any significant differences in seroprevalence across age strata so as to examine the validity of this assumption.

I calculated the number of infected people by multiplying the relevant population size and the adjusted estimate of seroprevalence. If a study did not give an adjusted seroprevalence estimate, I used the unadjusted seroprevalence instead. When seroprevalence estimates with different adjustments were available, I selected the analysis with largest adjustment. The factors adjusted for included COVID-19 test performance, sampling design, and other factors such as age, sex, clustering effects or socioeconomic factors. I did not adjust for specificity in test performance when positive antibody results were already validated by a different method.

For the number of COVID-19 deaths, I chose the number of deaths accumulated until the date 1 week after the midpoint of the study period (or the date closest to this that had available data) – unless the authors of the study had strong arguments to choose some other time point or approach. The 1-week lag accounts for different delays

in developing antibodies versus dying from infection. The number of deaths is an approximation because it is not known when exactly each patient who died was infected. The 1-week cut-off after the study midpoint may underestimate deaths in places where patients are in hospital for a long time before death, and may overestimate deaths in places where patients die soon because of poor or even inappropriate care. Whether or not the health system became overloaded may also affect the number of deaths. Moreover, because of imperfect diagnostic documentation, COVID-19 deaths may have been both overcounted and undercounted in different locations and at different time points.

I calculated the inferred infection fatality rate by dividing the number of deaths by the number of infected people for the entire population, and separately for people younger than 70 years. I took the proportion of COVID-19 deaths that occurred in people younger than 70 years from situational reports for the respective locations that I retrieved at the time I identified the seroprevalence studies. I also calculated a corrected infection fatality rate to try and account for the fact that only one or two types of antibodies (among IgG, IgM, IgA) might have been used. I corrected seroprevalence upwards (and inferred infection fatality rate downwards) by one tenth of its value if a study did not measure IgM and similarly if IgA was not measured. This correction is reasonable based on some early evidence,⁷ although there is uncertainty about the exact correction factor.

Data synthesis

The estimates of the infection fatality rate across all locations showed great heterogeneity with I^2 exceeding 99.9%; thus, a meta-analysis would be inappropriate to report across all locations. Quantitative synthesis with meta-analysis across all locations would also be misleading since locations with high COVID-19 seroprevalence would tend to carry more weight than locations with low seroprevalence. Furthermore, locations with more studies (typically those that have attracted more attention because of high death tolls and thus high infection fatality rates) would be represented multiple times in the calculations. In addition, poorly conducted studies with fewer adjustments would get more weight because of spu-

riously narrower confidence intervals than more rigorous studies with more careful adjustments which allow for more uncertainty. Finally, with a highly skewed distribution of the infection fatality rate and with large between-study heterogeneity, typical random effects models would produce an incorrectly high summary infection fatality rate that approximates the mean of the study-specific estimates (also strongly influenced by high-mortality locations where more studies have been done); for such a skewed distribution, the median is more appropriate.

Therefore, in a first step, I grouped estimates of the infection fatality rate from studies in the same country (or for the United States of America, the same state) together and calculated a single infection fatality rate for that location, weighting the study-specific infection fatality rates by the sample size of each study. This approach avoided inappropriately giving more weight to studies with higher seroprevalence estimates and those with seemingly narrower confidence intervals because of poor or no adjustments, while still giving more weight to larger studies. Then, I used the single summary estimate for each location to calculate the median of the distribution of location-specific infection fatality rate estimates. Finally, I explored whether the location-specific infection fatality rates were associated with the COVID-19 mortality rate in the population (COVID-19 deaths per million people) in each location as of 12 September 2020; this analysis allowed me to assess whether estimates of the infection fatality rate tended to be higher in locations with a higher burden of death from COVID-19.

Results

Seroprevalence studies

I retrieved 61 studies with 74 eligible estimates published either in the peer-reviewed literature or as preprints as of 9 September 2020.^{8–68} Furthermore, I considered another eight preliminary national estimates.^{69–76} This search yielded a total of 82 eligible estimates (Fig. 1).

The studies varied substantially in sampling and recruitment designs (Table 1; available at: <http://www.who.int/bulletin/volumes/99/1/20-265892>). Of the 61 studies, 24 studies^{8,10,16,17,20,22,25,33,34,36,37,42,46–49,52–54,57,61,63,65,68}

explicitly aimed for random sampling from the general population. In principle, random sampling is a stronger design. However, even then, people who cannot be reached (e.g. by email or telephone or even by visiting them at a house location) will not be recruited, and these vulnerable populations are likely to be missed. Moreover, several such studies^{8,10,16,37,42} focused on geographical locations with high numbers of deaths, higher than other locations in the same city or country, and this emphasis would tend to select eventually for a higher infection fatality rate on average.

Eleven studies assessed blood donors,^{12,15,18,24,28,31,41,44,45,55,60} which might underestimate COVID-19 seroprevalence in the general population. For example, 200 blood donors in Oise, France showed 3.00% seroprevalence, while the seroprevalence was 25.87% (171/661) in pupils, siblings, parents, teachers and staff at a high school with a cluster of cases in the same area; the true population seroprevalence may be between these two values.¹³


For other studies, healthy volunteer bias¹⁹ may underestimate seroprevalence, attracting people with symptoms²⁶ may overestimate seroprevalence, and studies of employees,^{14,21,25,32,66} grocery store clients²³ or patient cohorts^{11,14,27–30,36,38,40,50,51,56,59,62,64,67} risk sampling bias in an unpredictable direction.

All the studies tested for IgG antibodies but only about half also assessed IgM and few assessed IgA. Only seven studies assessed all three types of antibodies and/or used pan-Ig antibodies. The ratio of people sampled versus the total population of the region was more than 1:1000 in 20 studies (Table 2; available at: <http://www.who.int/bulletin/volumes/99/1/20-265892>).

Seroprevalence estimates

Seroprevalence for the infection ranged from 0.02% to 53.40% (58.40% in the slum sub-population in Mumbai; Table 3). Studies varied considerably depending on whether or not they tried to adjust their estimates for test performance, sampling (to get closer to a more representative sample), clustering (e.g. when including household members) and other factors. The adjusted seroprevalence occasionally differed substantially from the unadjusted value. In

Fig. 1. Flowchart for selection of seroprevalence studies on severe acute respiratory syndrome coronavirus 2, 2020



COVID-19: coronavirus disease 2019; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

studies that used samples from multiple locations, between-location heterogeneity was seen (e.g. 0.00–25.00% across 133 Brazilian cities).²⁵

Inferred infection fatality rate

Inferred infection fatality rate estimates varied from 0.00% to 1.63% (Table 4). Corrected values also varied considerably (0.00–1.54%).

For 15 locations, more than one estimate of the infection fatality rate was available and thus I could compare the infection fatality rate from different studies evaluating the same location. The estimates of infection fatality rate tended to be more homogeneous within each location, while they differed markedly across locations (Fig. 2). Within the same location, infection fatality rate estimates tend to have only small differences, even though it is possible that different areas within the same location may also have real differences in infection fatality rate. France is one exception where differences are large, but both estimates come from population studies of outbreaks from schools and thus may not provide good estimates of population seroprevalence and may lead to an underestimated infection fatality rate.

I used summary estimates weighted for sample size to generate a single estimate for each location. Data were available for 51 different locations (including the inferred infection fatality rates from the eight preliminary additional national estimates in Table 5).

The median infection fatality rate across all 51 locations was 0.27% (corrected 0.23%). Most data came from locations with high death tolls from COVID-19 and 32 of the locations had a population mortality rate (COVID-19 deaths per million population) higher than the global average (118 deaths from COVID-19 per million as of 12 September 2020;⁷⁹ Fig. 3). Uncorrected estimates of the infection fatality rate of COVID-19 ranged from 0.01% to 0.67% (median 0.10%) across the 19 locations with a population mortality rate for COVID-19 lower than the global average, from 0.07% to 0.73% (median 0.20%) across 17 locations with population mortality rate higher than the global average but lower than 500 COVID-19 deaths per million, and from 0.20% to 1.63% (median 0.71%) across 15 locations with more than 500 COVID-19 deaths per million. The corrected estimates of the median infection fatality rate were

Table 3. **Estimated prevalence of COVID-19 and estimated number of people infected, 2020**

Country (location)	Seroprevalence, %			Estimated no. of people infected
	Crude	Adjusted		
		Value	Adjustments	
Argentina (Barrio Padre Mugica) ⁴⁷	ND	53.4	Age, sex, household, non-response	26 691
Belgium ³⁸	5.7	6.0	Sampling, age, sex, province	695 377
Brazil (133 cities) ³⁵	1.39	1.62 overall (0 – 25.0 across the 133 cities)	Test, design	1 209 435 ^a
Brazil (Espírito Santo) ³⁴	2.1	ND	NA	84 391
Brazil (Maranhão) ⁶⁸	37	40.4	Clustering, stratification, non-response	2 877 454
Brazil (Rio de Janeiro), blood donors ⁴¹	6	4.7	Age, sex, test	811 452
Brazil (Rio Grande do Sul) ¹⁷	0.222	0.222 ^b	Sampling	25 283
Brazil (Sao Paulo) ⁴²	5.2	4.7	Sampling design	14 017
Canada (British Columbia) ⁵⁰	0.45	0.55	Age	27 890
Chile (Vitacura) ⁴³	11.2	ND	NA	9 500
China, blood donors ⁵⁵				
Wuhan	3.87	ND	NA	433 827
Shenzhen	0.06	ND	NA	7 818
Shijiazhuang	0.02	ND	NA	2 206
China (Wuhan) ¹⁴	10	ND	NA	1 108 000
China (Wuhan) ³²	8.36	ND	NA	926 288
Entire period	3.53	2.80	Age, sex, test	–
China (Guangzhou), blood donors ⁶⁰	0.09	ND	NA	104 783
China (several regions) ⁴⁰				
Hubei (not Wuhan)	3.6	ND	NA	1 718 110
Chongqing	3.8	ND	NA	11 956 109
Sichuan	0.6	ND	NA	487 847
Guangdong	2.2	ND	NA	2 522 010
Croatia ²⁶	1.27 ^c	ND	NA	51 765
Denmark, blood donors ¹²	2	1.9	Test	109 665
Denmark (Faroe Islands) ⁵²	0.6	0.7	Test	365
France (Crepy-en-Valois) ³⁹	10.4	ND	NA	620 105
France (Oise) ¹³	25.9	ND	NA	1 548 000
Germany (Gangelt) ¹⁶	15	20.0	Test, cluster, symptoms	2 519
Germany (Frankfurt) ²¹	0.6	ND	NA	16 086
Greece ⁶²	0.42 (April)	0.49 ^d	Age, sex, region	51 023
Hungary ⁵⁷	0.67	0.68	Design, age, sex, district	65 671
Iceland ⁵⁸	2.3 (quarantined), 0.3 (unknown exposure)	0.9	Including those positive by RT-PCR	3 177
India (Mumbai) ⁵¹				534 750
Slum areas	54.1	58.4	Test, age, sex	–
Non-slum areas	16.1	17.3	Test, age, sex	–
India (Srinagar) ⁵⁷	3.8	3.6	Age, sex	54 000
Islamic Republic of Iran (Guilan) ⁸	22	33.0	Test, sampling	770 000
Italy (Apulia), blood donors ³¹	0.99	ND	NA	39 887
Japan (Kobe) ¹¹	3.3	2.7	Age, sex	40 999
Japan (Tokyo) ²⁹	3.83	ND	NA	532 450
Japan (Utsunomiya City) ⁴⁸	0.4	1.23	Age, sex, distance to clinic, district, cohabitants	6 378
Kenya, blood donors ³⁴	5.6	5.2	Age, sex, region, test	2 783 453
Luxembourg ²⁰	1.9	2.1	Age, sex, district	12 684
Netherlands, blood donors ¹⁵	2.7	ND	NA	461 622
Netherlands (Rotterdam) ⁶⁴	3	ND	NA	512 910
Pakistan (Karachi) ⁴⁹	16.3	11.9	Age, sex	1 987 300
East	20.0	15.1	Age, sex	–
Malir	12.7	8.7	Age, sex	–
Pakistan (urban) ⁶⁶	17.5	ND	NA	13 825 000
Qatar ⁵¹	30.4	ND	NA	851 200

(continues. . .)

(. . .continued)

Country (location)	Seroprevalence, %			Estimated no. of people infected
	Crude	Adjusted		
		Value	Adjustments	
Entire period	24.0	ND	NA	–
Republic of Korea ⁵⁹	0.07	ND	NA	1 867
Spain ³⁶	ND	5.0 ^e	Sampling, age, sex, income	2 347 000
Spain (Barcelona) ³⁰	14.3	ND	NA	1 081 938
Switzerland (Geneva) ¹⁰	10.6	10.9	Test, age, sex	54 500
Switzerland ²⁸				
Zurich ^f	Unclear	1.3	Multivariate Gaussian conditioning	19 773
Zurich and Lucerne ⁹	Unclear	1.6	Multivariate Gaussian conditioning	30 888
United Kingdom (England) ⁶⁵	5.6	6.0	Test, sampling	3 360 000
United Kingdom (Scotland) blood donors ¹⁸	1.2	ND	NA	64 800
USA (10 states) ³⁵				
Washington, Puget Sound	1.3	1.1	Age, sex, test	48 291
Utah	2.4	2.2	Age, sex, test	71 550
New York, New York City	5.7	6.9	Age, sex, test	641 778
Missouri	2.9	2.7	Age, sex, test	161 936
Florida, south	2.2	1.9	Age, sex, test	117 389
Connecticut	4.9	4.9	Age, sex, test	176 012
Louisiana	ND	5.8	Age, sex, test	267 033
California, San Francisco Bay	ND	1	Age, sex, test	64 626
Pennsylvania, Philadelphia	ND	3.2	Age, sex, test	156 633
Minnesota, Minneapolis	ND	2.4	Age, sex, test	90 651
USA (California, Bay Area) blood donors ²⁴	0.4	0.1	Test and confirmation	7 753
USA (California, Los Angeles) ²²	4.06	4.65	Test, sex, race and ethnicity, income	367 000
USA (California, San Francisco), in census tract 022 901 ³³	4.3	6.1	Age, sex, race and ethnicity, test	316
USA (California, Santa Clara) ¹⁹	1.5	2.6	Test, sampling, cluster	51 000
USA (Idaho, Boise) ⁹	1.79	ND	NA	8620
USA (Georgia, DeKalb and Fulton counties) ⁵³	2.7	2.5	Age, sex, race and ethnicity	45 167
USA (Idaho, Blaine County) ⁴⁶	22.4	23.4	Test, age, sex, household	5 403
USA (Indiana) ⁵⁴	2.3 (IgG and RT-PCR) ^h	2.8	Age, race, Hispanic ethnicity	187 802
USA (Louisiana, Baton Rouge) ⁵³	6	6.6	Census, race, parish, including RT-PCR positives	46 147
USA (Louisiana, Orleans and Jefferson Parish) ³⁷	6.9 (IgG and RT-PCR) ^h	6.9 for IgG	Census weighting, demographics	56 578
USA (New York) ²³	12.5	14.0	Test, sex, age race and ethnicity, region	2 723 000
USA, New York ⁵⁶				
Columbia University Medical Center, New York City	5	ND	NA	463 044
CareMount central laboratory, five New York state counties	1.8	ND	NA	183 404
USA (New York, Brooklyn) ³⁷	47	ND	NA	1 203 154
USA (Rhode Island), blood donors ⁴⁵	3.9	ND	NA	41 384

COVID-19: coronavirus disease 2019; NA: not applicable; ND: no data available; RT-PCR: real-time polymerase chain reaction; test: test performance.

^a The authors calculated 760 000 to be infected in the 90 cities that had 200–250 samples tested, but many of the other 43 cities with < 200 samples may be equally or even better represented since they tended to be smaller than the 90 cities (mean population 356 213 versus 659 326).

^b An estimate is also provided adjusting for test performance, but the assumed specificity of 99.0% seems inappropriately low, since as part of the validation process the authors found that several of the test-positive individuals had household members who were also infected, thus the estimated specificity was deemed by the authors to be at least 99.95%.

^c 1.20% in workers in Split without mobility restrictions, 3.37% in workers in Knin without mobility restrictions, 1.57% for all workers without mobility restrictions; Split and Knin tended to have somewhat higher death rates than nationwide Croatia, but residence of workers is not given, so the entire population of the country is used in the calculations.

^d An estimate is also provided adjusting for test performance resulting in adjusted seroprevalence of 0.23%, but this seems inappropriately low, since the authors report that all positive results were further validated by ELISA (enzyme-linked immunosorbent assay).

^e 5.0% with point of care test, 4.6% with immunoassay, 3.7% with both tests positive, 6.2% with at least one test positive.

^f Patients during 1–15 April.

^g Blood donors in May.

^h The study counts in prevalence also those who were currently/recently infected as determined by a positive RT-PCR.

Notes: Of the studies where seroprevalence was evaluated at multiple consecutive time points, the seroprevalence estimate was the highest in the most recent time interval with few exceptions, for example: in the Switzerland (Geneva) study,¹⁰ the highest value was seen 2 weeks before the last time interval; in the Switzerland (Zurich) study,²⁸ the highest value was seen in the period 1–15 April for patients at the university hospital and in May for blood donors; and in the China (Wuhan) study,³² the highest value was seen about 3 weeks before the last time interval.

Table 4. Deaths from COVID-19 and inferred infection fatality rates, overall and in people younger than 70 years, by location, 2020

Location	No. of site-specific cumulative deaths from COVID-19 (to date) ^a	Inferred infection fatality rate, % (corrected)	% of site-specific cumulative deaths from COVID-19 in people < 70 years ^a	Infection fatality rate in people < 70 years, % (corrected)
Argentina (Barrio Padre Mugica) ⁴⁷	44 (1 July)	0.16 (0.13)	~70	0.11 (0.09)
Belgium ³⁸	7594 (30 April)	1.09 (0.87)	10	0.13 (0.10)
Brazil (133 cities) ²⁵	— ^b	Median 0.30 (0.27)	31 (< 60 years)	0.10 (0.09)
Brazil (Espírito Santo) ³⁴	363 (21 May)	0.43 (0.39)	31 (Brazil, < 60 years)	0.14 (0.13)
Brazil (Maranhão) ⁶⁸	4272 (8 August)	0.15 (0.14)	23	0.04 (0.03)
Brazil (Rio de Janeiro), blood donors ⁴¹	1019 (3 May)	0.12 (0.11)	31 (Brazil, < 60 years)	0.04 (0.04)
Brazil (Rio Grande do Sul) ¹⁷	124 (14 May)	0.49 (0.39)	31 (Brazil, < 60 years)	0.19 (0.15)
Brazil (Sao Paulo) ⁴²	NA ^c (15 May)	Unknown, but likely > 0.4	31 (Brazil, < 60 years)	Unknown, but likely > 0.1
Canada (British Columbia) ⁵⁰	164 (28 May)	0.59 (0.59)	13	0.08 (0.08)
Chile (Vitacura) ⁴³	NA ^c (18 May)	Unknown, but likely < 0.2	36 (Chile)	Unknown, but likely < 0.1
China, blood donors ⁵⁵				
Wuhan	1935 (20 February)	0.45 (0.41)	50	0.24 (0.22)
Shenzhen	1 (5 March)	0.01 (0.01)	About 50 (if similar to Wuhan)	0.01 (0.01)
Shijiazhuang	1 (27 February)	0.05 (0.04)	About 50 (if similar to Wuhan)	0.03 (0.02)
China (Wuhan) ¹⁴	3869 (2 May)	0.35 (0.31)	50	0.19 (0.15)
China (Wuhan) ³²	3869 (13 April)	0.42 (0.38)	50	0.23 (0.21)
China (Guangzhou), blood donors ⁶⁰	8 (5 April)	0.00 (0.00)	About 50 (if similar to Wuhan)	0.00 (0.00)
China (several regions) ⁴⁰				
Hubei (not Wuhan)	643 (12 April)	0.04 (0.03)	About 50 (if similar to Wuhan)	0.02 (0.02)
Chongqing	6 (12 April)	0.00 (0.00)	About 50 (if similar to Wuhan)	0.00 (0.00)
Guangdong	8 (12 April)	0.00 (0.00)	About 50 (if similar to Wuhan)	0.00 (0.00)
Sichuan	3 (12 April)	0.00 (0.00)	About 50 (if similar to Wuhan)	0.00 (0.00)
Croatia ²⁶	79 (3 May)	0.15 (0.14)	13	0.02 (0.02)
Denmark, blood donors ¹²	370 (21 April)	0.34 (0.27)	12	0.05 (0.04)
Faroe Islands ⁵²	0 (5 May)	0.00 (0.00)	0	0.00 (0.00)
France (Creppey-en-Valois) ³⁹	2325 (5 May) ^d	0.37 (0.30)	7 (France, < 65 years)	0.04 (0.03)
France (Oise) ¹³	932 (7 April) ^d	0.06 (0.05)	7 (France, < 65 years)	0.01 (0.01)
Germany (Gangelt) ¹⁶	7 (15 April)	0.28 (0.25)	0	0.00 (0.00)
Germany (Frankfurt) ²¹	42 ^e (17 April)	0.26 (0.21)	14 (Germany)	0.04 (0.03)
Greece ⁶²	121 (22 April)	0.24 (0.19)	30	0.09 (0.07)
Hungary ⁵⁷	442 (15 May)	0.67 (0.54)	No data	No data
Iceland ⁵⁸	10 (1 June)	0.30 (0.30)	30	0.10 (0.10)
India (Mumbai) ⁶¹	495 (13–20 July)	0.09 (0.07)	50 (< 60 years, India)	0.04 (0.03)
India (Srinagar) ⁶⁷	35 (15 July) ^f	0.06 (0.05)	50 (< 60 years, India)	0.03 (0.03)
Islamic Republic of Iran (Guilan) ⁸	617 (23 April)	0.08 (0.07)	No data	No data
Italy (Apulia), blood donors ³¹	530 (22 May)	1.33 (1.20)	15 (Italy)	0.24 (0.22)
Japan (Kobe) ¹¹	10 (mid-April)	0.02 (0.02)	21 (Japan)	0.01 (0.01)
Japan (Tokyo) ²⁹	189 (11 May)	0.04 (0.03)	21 (Japan)	0.01 (0.01)
Japan (Utsunomiya City) ⁴⁸	0 (14 June)	0.00 (0.00)	0	0.00 (0.00)
Kenya, blood donors ⁴⁴	64 (31 May)	0.00 (0.00)	58 (< 60 years)	0.00 (0.00)
Luxembourg ²⁰	92 (2 May)	0.73 (0.58)	9	0.07 (0.06)
Netherlands, blood donors ¹⁵	3134 (15 April)	0.68 (0.68)	11	0.09 (0.09)
Netherlands (Rotterdam) ⁶⁴	3134 (15 April)	0.65 (0.52)	11	0.08 (0.06)
Pakistan (Karachi) ⁴⁹	~1500 (9 July) ^g	0.08 (0.07)	~70	0.06 (0.05)
Pakistan (urban) ⁶⁶	5266 (13 July) ^h	0.04 (0.04)	~70	0.03 (0.03)
Qatar ⁵¹	93 (19 June)	0.01 (0.01)	74	0.01 (0.01)
Republic of Korea ⁵⁹	2 (3 June) ⁱ	0.10 (0.09)	0	0.00 (0.00)
Spain ³⁶	26 920 (11 May)	1.15 (0.92)	13	0.18 (0.14)
Spain (Barcelona) ³⁰	5137 (2 May)	0.48 (0.48)	13 (Spain)	0.07 (0.07)
Switzerland (Geneva) ¹⁰	243 (30 April)	0.45 (0.36)	8	0.04 (0.03)

(continues. . .)

(. . .continued)

Location	No. of site-specific cumulative deaths from COVID-19 (to date) ^a	Inferred infection fatality rate, % (corrected)	% of site-specific cumulative deaths from COVID-19 in people < 70 years ^a	Infection fatality rate in people < 70 years, % (corrected)
Switzerland (Zurich) ²⁸	107 (15 April, Zurich), 147 (22 May, Zurich and Lucerne)	0.51 (0.41)	8 (Switzerland)	0.05 (0.04)
England ⁵⁵	38 854 (9 July)	1.16 (0.93)	20	0.27 (0.22)
Scotland, blood donors ¹⁸	47 (1 April)	0.07 (0.06)	9 (< 65 years)	0.01 (0.01)
USA (10 states) ³⁵				
Washington, Puget Sound	207 (4 April)	0.43 (0.43)	10 (state, < 60 years)	0.05 (0.05)
Utah	58 (4 May)	0.08 (0.08)	28 (< 65 years)	0.03 (0.03)
New York	4146 (4 April)	0.65 (0.65)	34 (state)	0.25 (0.25)
Missouri	329 (30 April)	0.20 (0.20)	23	0.05 (0.05)
Florida, south	295 (15 April)	0.25 (0.25)	28 (state)	0.08 (0.08)
Connecticut	2718 (6 May)	1.54 (1.54)	18	0.31 (0.31)
Louisiana	806 (11 April)	0.30 (0.30)	32	0.10 (0.10)
California, San Francisco Bay	321 (1 May)	0.50 (0.50)	25	0.14 (0.14)
Pennsylvania, Philadelphia	697 (26 April)	0.45 (0.45)	21 (state)	0.10 (0.10)
Minnesota, Minneapolis	436 (13 May)	0.48 (0.48)	20 (state)	0.10 (0.10)
USA (California, Bay Area) ²⁴	12 (22 March)	0.15 (0.12)	25	0.04 (0.03)
USA (California, Los Angeles) ²²	724 (19 April)	0.20 (0.18)	24 (< 65 years)	0.06 (0.05)
USA (California, San Francisco) ³³	0 (4 May)	0.00 (0.00)	0	0.00 (0.00)
USA (California, Santa Clara) ¹⁹	94 (22 April)	0.18 (0.17)	35	0.07 (0.06)
USA (Idaho, Boise) ⁹	14 (24 April)	0.16 (0.13)	14 (Idaho)	0.02 (0.02)
USA (Georgia) ⁵³	198 (7 May)	0.44 (0.44)	30	0.15 (0.15)
USA (Idaho, Blaine County) ⁴⁶	5 (19 May)	0.10 (0.08)	14 (Idaho)	0.02 (0.01)
USA (Indiana) ⁵⁴	1099 (30 April)	0.58 (0.46)	24	0.16 (0.13)
USA (Louisiana, Baton Rouge) ⁶³	420 (30 July)	0.91 (0.73)	32 (Louisiana)	0.32 (0.25)
USA (Louisiana, Orleans and Jefferson Parish) ³⁷	925 (16 May)	1.63 (1.31)	32	0.57 (0.46)
USA (New York) ²³	18 610 (30 April) ^j	0.68 (0.54) ^j	34	0.26 (0.23)
USA (New York Columbia University Medical Center, New York City and CareMount central laboratory, five New York state counties) ³⁶	965 (28 March, New York state)	0.15 (0.14)	34	0.06 (0.05)
USA (New York, Brooklyn) ²⁷	4894 (19 May) ^j	0.41 (0.33) ^j	34 (New York state)	0.15 (0.14)
USA (Rhode Island), blood donors ⁴⁵	430 (11 May)	1.04 (0.83)	17	0.20 (0.16)

COVID-19: coronavirus disease 2019; NA: not available.

^a Whenever the number or proportion of COVID-19 deaths at age < 70 years was not provided in the paper, I retrieved the proportion of these deaths from situation reports of the relevant location. If I could not find this information for the specific location, I used a larger geographic area. For Brazil, the closest information that I found was from a news report.⁷⁷ For Croatia, I retrieved data on age for 45/103 deaths through Wikipedia.⁷⁸ Geographical location in parentheses specifies the population

^b Data are provided by the authors for deaths per 100 000 population in each city along with inferred infection fatality rate in each city, with wide differences across cities; the infection fatality rate shown here is the median across the 36 cities with 200–250 samples and at least one positive sample (the interquartile range for the uncorrected infection fatality rate is 0.20–0.60% and across all cities is 0–2.4%, but with very wide uncertainty in each city). A higher infection fatality rate is alluded to in the preprint, but the preprint also shows a scatter diagram for survey-based seroprevalence versus reported deaths per population with a regression slope that agrees with an infection fatality rate of 0.3%.

^c Information on deaths was not available for the specific locations. In the Sao Paulo study, the authors selected six districts of Sao Paulo most affected by COVID-19; they do not name the districts and the number of deaths as of mid-May is not available, but using data for death rates across all Sao Paulo would give an infection fatality rate of > 0.4% overall. In the Vitacura study, similarly one can infer from the wider Santiago metropolitan area that the infection fatality rate in the Vitacura area would probably be < 0.2% overall.

^d For France, government situation reports provide the number of deaths per region only for in-hospital deaths; therefore, I multiplied the number of in-hospital deaths by a factor equal to: total number of deaths/in-hospital deaths for all of France.

^e Estimated from number of deaths in Hesse province on 17 April × proportion of deaths in the nine districts with key enrolment (enrolment ratio > 1:10 000) in the study among all deaths in Hesse province.

^f I calculated the approximate number of deaths assuming the same case fatality ratio in the Srinagar district as in the Jammu and Kashmir state where it is located.

^g For Karachi, it is assumed that about 30% of COVID-19 deaths in Pakistan are in Karachi (since about 30% of the cases are there).

^h The number of deaths across all Pakistan; I assumed that this number is a good approximation of deaths in urban areas (most deaths occur in urban areas and there is some potential underreporting).

ⁱ I calculated the approximate number of deaths from the number of cases in the study areas in south-western Seoul, assuming a similar case fatality as in Seoul overall.

^j Confirmed COVID-19 deaths; inclusion of probable COVID-19 deaths would increase the infection fatality rate estimates by about a quarter.

Note: Cumulative deaths are sourced from the specific study or from situation report on the same location unless otherwise stated.

0.09%, 0.20% and 0.57%, respectively, for the three location groups.

For people younger than 70 years old, the infection fatality rate of COVID-19 across 40 locations with available data ranged from 0.00% to 0.31% (median 0.05%); the corrected values were similar.


Discussion

The infection fatality rate is not a fixed physical constant and it can vary substantially across locations, depending on the population structure, the case-mix of infected and deceased individuals and other, local factors. The studies analysed here represent 82 different estimates of the infection fatality rate of COVID-19, but they are not fully representative of all countries and locations around the world. Most of the studies are from locations with overall COVID-19 mortality rates that are higher than the global average. The inferred median infection fatality rate in locations with a COVID-19 mortality rate lower than the global average is low (0.09%). If one could sample equally from all locations globally, the median infection fatality rate might even be substantially lower than the 0.23% observed in my analysis.

COVID-19 has a very steep age gradient for risk of death.⁸⁰ Moreover, in European countries that have had large numbers of cases and deaths⁸¹, and in the USA⁸², many, and in some cases most, deaths occurred in nursing homes. Locations with many nursing home deaths may have high estimates of the infection fatality rate, but the infection fatality rate would still be low among non-elderly, non-debilitated people.

Within China, the much higher infection fatality rate estimates in Wuhan compared with other areas of the country may reflect widespread nosocomial infections,⁸³ as well as unfamiliarity with how to manage the infection as the first location that had to deal with COVID-19. The very many deaths in nursing homes, nosocomial infections and overwhelmed hospitals may also explain the high number of fatalities in specific locations in Italy⁸⁴ and New York and neighbouring states.^{23,27,35,56} Poor decisions (e.g. sending COVID-19 patients to nursing homes), poor management (e.g. unnecessary mechanical ventilation and hydroxychloroquine) may also have contributed to worse outcomes.

Fig. 2. Estimates of infection fatality rates for COVID-19 in locations that had two or more estimates, 2020



COVID-19: coronavirus disease 2019.

Notes: Locations are defined at the level of countries, except for the United States of America where they are defined at the level of states and China is separated into Wuhan and non-Wuhan areas. Corrected infection fatality rate estimates are shown (correcting for what types of antibodies were assayed).

High levels of congestion (e.g. in busy public transport systems) may also have exposed many people to high infectious loads and, thus, perhaps more severe disease. A more aggressive viral clade has also been speculated.⁸⁵ The

infection fatality rate may be very high among disadvantaged populations and in settings with a combination of factors predisposing to higher fatalities.³⁷ Very low infection fatality rates seem common in Asian coun-

Table 5. Infection fatality rates for COVID-19 inferred from preliminary nationwide seroprevalence data, 2020

Country	Sample size	Date	Reported seroprevalence (%)	Population, no.	Deaths, no. (date)	Inferred infection fatality rate (corrected), %
Afghanistan ⁷⁵	9 500 (NR)	NR	31.5	39 021 453	1 300 (8 May)	0.01 (0.01)
Czechia ⁷¹	26 549 (IgG)	23 April–1 May	0.4	10 710 000	252 (4 May)	0.59 (0.47)
Finland ⁶⁹	674 (IgG)	20–26 April ^a	2.52	5 541 000	211 (30 April)	0.15 (0.12)
Georgia ⁷⁶	1 068 (NR)	18–27 May	1	3 988 264	12 (30 May)	0.03 (0.03) ^b
Israel ⁷²	1 709 (NR)	May	2–3	9 198 000	299 (10 June)	0.13 (0.10) ^c
Russian Federation ⁷⁴	650 000 (NR)	NR	14	145 941 776	5 859 (7 June)	0.03 (0.03)
Slovenia ⁷³	1 368 (NR)	April	3.1	2 079 000	92 (1 May)	0.14 (0.11)
Sweden ⁷⁰	1 200 (IgG)	18–24 May	6.3	10 101 000	4 501 (28 May)	0.71 (0.57)

COVID-19: coronavirus disease 2019; Ig: immunoglobulin; NR: not reported.

^a The seroprevalence was slightly lower in subsequent weeks.

^b The survey was done in Tbilisi, the capital city with a population 1.1 million. I could not retrieve the count of deaths in Tbilisi, but if more deaths happened in Tbilisi, then the infection fatality rate may be higher, but still < 0.1%.

^c Assuming a seroprevalence of 2.5%.


Notes: These are countries for which no eligible studies were retrieved in the literature search. The results of these studies have been announced to the press and/or in preliminary reports, but are not yet peer reviewed and published.

tries.^{8,11,29,48,49,51,59,61,67} A younger population in these countries (excluding Japan), previous immunity from exposure to other coronaviruses, genetic differences, hygiene etiquette, lower infectious load and other unknown factors may explain these low rates. The infection fatality rate is low also in low-income countries in both Asia and Africa,^{44,49,66,67} perhaps reflecting the young age structure. However, comorbidities, poverty, frailty (e.g. malnutrition) and congested urban living circumstances may have an adverse effect on risk and thus increase infection fatality rate.

Antibody titres may decline with time^{10,28,32,86,87} and this would give falsely low prevalence estimates. I considered the maximum seroprevalence estimate when multiple repeated measurements at different time points were available, but even then some of this decline cannot be fully accounted for. With four exceptions,^{10,28,32,51} the maximum seroprevalence value was at the latest time point.

Positive controls for the antibody assays used were typically symptomatic patients with positive polymerase chain reaction tests. Symptomatic patients may be more likely to develop antibodies.^{87–91} Since seroprevalence studies specifically try to reveal undiagnosed asymptomatic and mildly symptomatic infections, a lower sensitivity for these mild infections could lead to substantial underestimates of the number of

Fig. 3. Corrected estimates of COVID-19 infection fatality rate in each location plotted against COVID-19 cumulative deaths per million as of September 12 2020 in that location



COVID-19: coronavirus disease 2019.

Notes: Locations are defined at the level of countries, except for the United Kingdom of Great Britain and Northern Ireland where they are defined by jurisdiction, United States of America (USA) are defined at the level of states and China is separated into Wuhan and non-Wuhan areas. Included locations are: Afghanistan; Argentina; Belgium; Brazil; Canada; Chile; China (non-Wuhan and Wuhan); Croatia; Czechia; Denmark; Faroe Islands; Finland; France; Georgia; Germany; Greece; Hungary; Iceland; India; Iran (Islamic Republic of); Israel; Italy; Japan; Kenya; Luxembourg; Netherlands; Pakistan; Qatar; Republic of Korea; Russian Federation; Slovenia; Spain; Sweden; Switzerland; United Kingdom (England, Scotland); and USA (California, Connecticut, Florida, Georgia, Idaho, Indiana, Louisiana, Minnesota, Missouri, New York, Pennsylvania, Rhode Island, Utah, Washington). When several infection fatality rate estimates were available from multiple studies for a location, the sample size-weighted mean is used. One outlier location with very high deaths per million population (1702 for New York) is not shown.

infected people and overestimates of the inferred infection fatality rate.

A main issue with seroprevalence studies is whether they offer a representative picture of the population in the assessed region. A generic problem is that vulnerable people at high risk of infection and/or death may be more difficult to recruit in survey-type studies. COVID-19 infection is particularly widespread and/or lethal in nursing homes, in homeless people, in prisons and in disadvantaged minorities.⁹² Most of these populations are very difficult, or even impossible, to reach and sample and they are probably under-represented to various degrees (or even entirely missed) in surveys. This sampling obstacle would result in underestimating the seroprevalence and overestimating infection fatality rate.

In principle, adjusted seroprevalence values may be closer to the true estimate, but the adjustments show that each study alone may have unavoidable uncertainty and fluctuation, depending on the type of analysis chosen. Furthermore, my corrected infection fatality rate estimates try to account for undercounting of infected people when not

all three antibodies (IgG, IgM and IgA) were assessed. However, the magnitude of the correction is uncertain and may vary in different circumstances. An unknown proportion of people may have responded to the virus using immune mechanisms (mucosal, innate, cellular) without generating any detectable serum antibodies.⁹³⁻⁹⁷

A limitation of this analysis is that several studies included have not yet been fully peer-reviewed and some are still ongoing. Moreover, despite efforts made by seroprevalence studies to generate estimates applicable to the general population, representativeness is difficult to ensure, even for the most rigorous studies and despite adjustments made. Estimating a single infection fatality rate value for a whole country or state can be misleading, when there is often huge variation in the population mixing patterns and pockets of high or low mortality. Furthermore, many studies have evaluated people within restricted age ranges, and the age groups that are not included may differ in seroprevalence. Statistically significant, modest differences in seroprevalence across some age groups have been observed in several

studies.^{10,13,15,23,27,36,38} Lower values have been seen in young children and higher values in adolescents and young adults, but these patterns are inconsistent and not strong enough to suggest that major differences are incurred by extrapolating across age groups.

Acknowledging these limitations, based on the currently available data, one may project that over half a billion people have been infected as of 12 September 2020, far more than the approximately 29 million documented laboratory-confirmed cases. Most locations probably have an infection fatality rate less than 0.20% and with appropriate, precise non-pharmacological measures that selectively try to protect high-risk vulnerable populations and settings, the infection fatality rate may be brought even lower. ■

Funding: METRICS has been supported by a grant from the Laura and John Arnold Foundation.

Competing interests: I am a co-author (not principal investigator) of one of the seroprevalence studies.

ملخص

معدل وفيات عدوى كوفيد 19 المستدل عليه من بيانات الانتشار المصلي

0.27% (تصحيح بنسبة 0.23%): كان المعدل 0.09% في المواقع التي تقل فيها معدلات وفيات السكان المصابين بكوفيد 19 عن المتوسط العالمي (أكثر من 118 حالة وفاة/مليون نسمة)، و0.20% في المواقع التي يوجد بها من 118 إلى 500 حالة وفاة/مليون نسمة مصابين بكوفيد 19، و0.57% في مواقعها أكثر من 500 حالة وفاة/مليون نسمة بسبب كوفيد 19. في الأشخاص الذين تقل أعمارهم عن 70 عامًا، تراوحت معدلات وفيات الإصابة بالعدوى من 0.00% إلى 0.31% بمتوسطات مبدئية ومصححة قدرها 0.05%.

الاستنتاج يمكن أن يختلف معدل وفيات الإصابة بفيروس كوفيد 19 بشكل كبير عبر المواقع المختلفة، وقد يعكس هذا الاختلافات في التركيب العمري للسكان، ومزيج الحالات من المرضى المصابين والمتوفين، وعوامل أخرى. تميل معدلات الوفيات المستدل عنها من العدوى إلى أن تكون أقل بكثير من التقديرات التي تم إجراؤها في وقت سابق في الجائحة.

الغرض تقدير معدل الوفيات الناجمة عن الإصابة بمرض فيروس كورونا 2019 (كوفيد 19) من بيانات الانتشار المصلي.

الطريقة قمت بالبحث في خوادم PubMed وخوادم ما قبل الطباعة عن دراسات الانتشار المصلي لكوفيد 19، بحجم عينة أكبر من أو تساوي 500 بدءًا من 9 سبتمبر/أيلول 2020. كما أنني استرجعت النتائج الإضافية للدراسات الوطنية من البيانات الصحفية والتقارير الأولية. قمت بتقييم دراسات ميزات التصميم وتقديرات الانتشار المصلي. لقد قمت بتقدير معدل الوفيات الناجمة عن الإصابة لكل دراسة عن طريق قسمة العدد الإجمالي للوفيات الناتجة عن جائحة كوفيد 19، على عدد الأشخاص المقدر إصابتهم في كل منطقة. وقمت بتصحيح عدد أنواع الأجسام المضادة التي تم اختبارها (الغلوتين المناعي، IgG، IgM، IgA).

النتائج قمت بتضمين 61 دراسة (74 تقديرًا) وثمانية تقديرات وطنية أولية. تراوحت تقديرات الانتشار المصلي من 0.02% إلى 53.40%. تراوحت معدلات وفيات العدوى من 0.00% إلى 1.63%، وتم تصحيح القيم من 0.00% إلى 1.54%. عبر 51 موقعًا، كان متوسط معدل وفيات عدوى كوفيد 19 هو

摘要

根据血清阳性率数据推断新型冠状病毒肺炎的感染死亡率

目的 根据血清阳性率数据估计 2019 年冠状病毒病（新型冠状病毒肺炎）的感染死亡率。

方法 在 PubMed 和预印本服务器上查找截至 2020 年 9 月 9 日新型冠状病毒肺炎相关的血清阳性率研究，样本量为 500 个。另外根据初步新闻稿和报告检索了其他全国性研究结果。并评估了与设计特征和血清阳性率估计值相关的研究。通过将新型冠状病毒肺炎累计死亡人数除以每个地区估计感染人数，估算出了每项研究的感染死亡率。然后校正了测试的抗体类型（免疫球蛋白、免疫球蛋白 G、免疫球蛋白 M、免疫球蛋白 A）的数量。

结果 我汇总了 61 项研究（74 个估计值）和 8 个全国性初步估计值。血清阳性率估计值介于 0.02% 至 53.40% 之间。感染死亡率介于 0.00% 至 1.63% 之间，校正值则介于 0.00% 至 1.54% 之间。在 51 个地区中，

新型冠状病毒肺炎感染死亡率的中位数为 0.27%（校正值为 0.23%）：在新型冠状病毒肺炎导致的人口死亡率低于全球平均水平（每一百万人口中死亡病例小于 118 例）的地区中，该比率为 0.09%；在每一百万人口中新型冠状病毒肺炎死亡病例介于 118–500 例之间的地区，该比率为 0.20%；而在每一百万人口中新型冠状病毒肺炎死亡病例大于 500 例的地区，该比率则为 0.57%。70 岁以下人群的感染死亡率介于 0.00% 至 0.31% 之间，经粗略校正后该比率的中位数为 0.05%。**结论** 不同地区的新型冠状病毒肺炎感染死亡率可能存在很大的差异，据此可反映出在人口年龄结构、感染和死亡病例组合以及其他因素方面存在差异。推断的感染死亡率往往比全球性流行病爆发初期的估计值要低得多。

Résumé

Ratio de létalité réel de la COVID-19 déduit à partir des données de séroprévalence

Objectif Estimer le ratio de létalité réel de la maladie à coronavirus 2019 (COVID-19) à partir des données de séroprévalence.

Méthodes J'ai effectué des recherches sur PubMed et sur les serveurs de prépublication afin de trouver des études consacrées à la séroprévalence de la COVID-19, avec des échantillons ≥ 500 , au 9 septembre 2020. J'ai également prélevé des résultats supplémentaires dérivés d'études nationales qui figurent dans les versions préliminaires de divers rapports et communiqués de presse. J'ai analysé les études pour y déceler des caractéristiques de conception et des estimations de séroprévalence. Ensuite, j'ai calculé le ratio de létalité réel pour chaque étude en divisant le nombre cumulé de décès dus à la COVID-19 par le nombre d'individus qui auraient été infectés dans chaque région. Enfin, j'ai apporté des corrections en fonction des types d'anticorps testés (immunoglobulines, IgG, IgM, IgA).

Résultats J'ai pris 61 études en compte (74 estimations) et huit estimations nationales préliminaires. Les estimations en matière de séroprévalence étaient comprises entre 0,02% et 53,40%. Les ratios de

létalité réels allaient de 0,00% à 1,63%, les valeurs corrigées de 0,00% à 1,54%. Dans les 51 lieux étudiés, la médiane du ratio de létalité réel pour la COVID-19 s'élevait à 0,27% (0,23% après correction): le ratio était de 0,09% dans les endroits où le taux de mortalité dû à la COVID-19 était inférieur à la moyenne mondiale (< 118 décès/million d'habitants), de 0,20% dans les endroits dénombant 118–500 décès COVID-19/million d'habitants, et de 0,57% là où la COVID-19 était responsable de > 500 décès/million d'habitants. Chez les personnes de moins de 70 ans, les ratios de létalité réels se situaient entre 0,00% et 0,31% avec des médianes brutes et corrigées de 0,05%.

Conclusion Le ratio de létalité réel de la COVID-19 peut considérablement varier d'un endroit à l'autre, ce qui pourrait correspondre aux différences de structure de pyramide des âges au sein de la population, au cas-mix entre patients infectés et décédés, ainsi qu'à d'autres facteurs. Les ratios de létalité réels que j'ai pu déduire avaient tendance à être nettement inférieurs aux estimations formulées précédemment durant la pandémie.

Резюме

Показатель летальности при инфицировании COVID-19, определенный на основании данных о серораспространенности

Цель Оценить показатель летальности при инфицировании коронавирусным заболеванием 2019 г. (COVID-19) на основании данных о серораспространенности.

Методы Автор провел поиск на серверах PubMed и серверах предварительной публикации на предмет исследований серораспространенности COVID-19 с размером выборки ≥ 500 по состоянию на 9 сентября 2020 года. Были также получены дополнительные результаты национальных исследований из предварительных пресс-релизов и отчетов. Автор оценил исследования по элементам дизайна и оценкам серораспространенности. Автор оценил показатель летальности при инфицировании для каждого исследования, разделив общее количество смертей от COVID-19 на количество людей, предположительно инфицированных в каждом регионе. При этом была сделана поправка на количество протестированных типов антител (иммуноглобулины, IgG, IgM, IgA).

Результаты В работу вошло 61 исследование (74 прогноза) и восемь предварительных национальных прогнозов. Прогнозы серораспространенности варьировались в диапазоне от 0,02 до 53,40%. Показатели летальности при инфицировании варьировались в диапазоне от 0,00 до 1,63%, скорректированные значения — от 0,00 до 1,54%. В 51 регионе средний показатель летальности при инфицировании COVID-19 составил 0,27% (скорректированный показатель 0,23%): этот показатель составил 0,09% в регионах с уровнем летальности населения от COVID-19 ниже, чем в среднем по миру (< 118 смертей на миллион), 0,20% в регионах, в которых зарегистрировано 118–500 случаев смерти от COVID-19 на миллион человек, и 0,57% в регионах, где зарегистрировано более 500 случаев смерти от COVID-19 на миллион человек. У людей младше 70 лет показатель летальности при инфицировании колебался в пределах от 0,00 до

0,31% с приблизительными и скорректированными медианными значениями 0,05%.

Вывод Показатель летальности при инфицировании COVID-19 может существенно различаться в разных регионах, и это может отражать различия в возрастной структуре населения,

структуре случаев инфицирования и смерти пациентов, а также в других факторах. Предполагаемые показатели летальности при инфицировании, как правило, были намного ниже, чем прогнозы, сделанные ранее во время пандемии.

Resumen

Tasa de letalidad por la infección de la COVID-19 calculada a partir de los datos de seroprevalencia

Objetivo Estimar la tasa de letalidad por la infección de la enfermedad por coronavirus de 2019 (COVID-19) a partir de los datos de seroprevalencia.

Métodos Se buscaron los estudios de seroprevalencia de la COVID-19 con un tamaño de muestra mayor o igual a 500 a partir del 9 de septiembre de 2020 en PubMed y en los servidores de preimpresión. Además, se recuperaron los resultados adicionales de los estudios nacionales a partir de los comunicados de prensa y de los informes preliminares. Se evaluaron los estudios para determinar las características de diseño y las estimaciones de seroprevalencia. Para calcular la tasa de letalidad por la infección de cada estudio, se dividió la cantidad acumulada de muertes por la COVID-19 por la cantidad de personas que se estima que están infectadas en cada región. Asimismo, se corrigió la cantidad de tipos de anticuerpos probados (inmunoglobulinas, IgG, IgM, IgA).

Resultados Se incluyeron 61 estudios (74 estimaciones) y 8 estimaciones nacionales preliminares. Las estimaciones de seroprevalencia oscilaban

entre el 0,02 % y el 53,40 %. Las tasas de letalidad por la infección oscilaron entre el 0,00 % y el 1,63 %, los valores corregidos entre el 0,00 % y el 1,54 %. En 51 lugares, la mediana de la tasa de letalidad por la infección de la COVID-19 fue del 0,27 % (corregida en un 0,23 %): la tasa fue del 0,09 % en lugares donde las tasas de letalidad de la población con la COVID-19 eran inferiores al promedio mundial (menos de 118 muertes/millón), del 0,20 % en lugares con 118-500 muertes a causa de la COVID-19/millón de personas y del 0,57 % en lugares con más de 500 muertes a causa de la COVID-19/millón de personas. En personas menores de 70 años, las tasas de letalidad por la infección oscilaron entre el 0,00 % y el 0,31 % con medianas brutas y corregidas del 0,05 %.

Conclusión La tasa de letalidad por infección de la COVID-19 puede variar de manera sustancial en diferentes lugares y esto puede reflejar diferencias en la estructura de edad de la población y en la variedad de casos de los pacientes infectados y fallecidos, así como en otros factores. Las tasas de letalidad por infección que se calculan tienden a ser mucho más bajas que las estimaciones realizadas a principios de la pandemia.

References

- Melnick ER, Ioannidis JPA. Should governments continue lockdown to slow the spread of covid-19? *BMJ*. 2020 Jun 3;369:m1924. doi: <http://dx.doi.org/10.1136/bmj.m1924> PMID: 32493767
- WHO Director-General's opening remarks at the media briefing on COVID-19 – 3 March 2020. Geneva: World Health Organization; 2020. Available from: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020> [cited 2020 May 10].
- Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16–24 February 2020. Geneva: World Health Organization; 2020. Available from: [https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-\(covid-19\)](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)) [cited 2020 May 10].
- McGinty JC. How many people might one person with coronavirus infect? *Wall Street Journal*. February 14, 2020. Available from: <https://www.wsj.com/articles/how-many-people-might-one-person-with-coronavirus-infect-11581676200> [cited 2020 Feb 27].
- Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. London: Imperial College; 2020. Available from: <https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf> [cited 2020 May 10].
- Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates [online ahead of print]. *Int J Infect Dis*. 2020 Sep 29;S1201(20):32180–9. PMID: 33007452
- García-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. *Nat Commun*. 2020 Jul 8;11(1):3500. doi: <http://dx.doi.org/10.1038/s41467-020-17318-x> PMID: 32641730
- Shakiba M, Nazari S, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.04.26.20079244>doi: <http://dx.doi.org/10.1101/2020.04.26.20079244>
- Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. *J Clin Microbiol*. 2020 Jul 23;58(8):e00941–20. doi: <http://dx.doi.org/10.1128/JCM.00941-20> PMID: 32381641
- Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*. 2020 Aug 1;396(10247):313–19. doi: [http://dx.doi.org/10.1016/S0140-6736\(20\)31304-0](http://dx.doi.org/10.1016/S0140-6736(20)31304-0) PMID: 32534626
- Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.04.26.20079822>doi: <http://dx.doi.org/10.1101/2020.04.26.20079822>
- Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. *Clin Infect Dis*. 2020 Jun 25; ciaa849. doi: <http://dx.doi.org/10.1093/cid/ciaa849> PMID: 32584966
- Fontanet A, Tondeur L, Madec Y, Grant R, Besombes C, Jolly N, et al. Cluster of COVID-19 in northern France: a retrospective closed cohort study [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.04.18.20071134>doi: <http://dx.doi.org/10.1101/2020.04.18.20071134>
- Wu X, Fu B, Chen L, Feng Y. Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China. *J Med Virol*. 2020 Apr 20;92(10):1795–6. doi: <http://dx.doi.org/10.1002/jmv.25904> PMID: 32311142
- Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat HM, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak [preprint]. Durham: Research Square; 2020. doi: <http://dx.doi.org/https://doi.org/10.21203/rs.3.rs-25862/v1>doi: <http://dx.doi.org/10.21203/rs.3.rs-25862/v1>
- Streeck H, Schulte B, Kümmerer BM, Richter E, Höller T, Fuhrmann C, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.04.20090076>doi: <http://dx.doi.org/10.1101/2020.05.04.20090076>

17. Silveira MF, Barros AJD, Horta BL, Pellanda LC, Victora GD, Dellagostin OA, et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. *Nat Med*. 2020 Aug;26(8):1196–9. doi: <http://dx.doi.org/10.1038/s41591-020-0992-3> PMID: 32641783
18. Thompson C, Grayson N, Paton RS, Lourenco J, Penman BS, Lee L. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors – a pilot study of the value of serology to determine population exposure [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.04.13.20060467>
19. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.04.14.20062463>
20. Snoeck CJ, Vaillant M, Abdelrahman T, Satagopam VP, Turner JD, Beaumont K, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.11.20092916>
21. Kraehling V, Kern M, Halwe S, Mueller H, Rohde C, Savini M, et al. Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.20.20107730>
22. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles County, California, on April 10–11, 2020. *JAMA*. 2020 06 16;323(23):2425–7. doi: <http://dx.doi.org/10.1001/jama.2020.8279> PMID: 32421144
23. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. *Ann Epidemiol*. 2020 Aug;48:23–29.e4. doi: <http://dx.doi.org/10.1016/j.annepidem.2020.06.004> PMID: 32648546
24. Ng D, Goldgof G, Shy B, Levine A, Balcerak J, Bapat SP, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.19.20107482>
25. Hallal PC, Hartwig FP, Horta BL, Victora GD, Silveira MF, Struchiner CJ, et al. Remarkable variability in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological household survey in 27 states [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.30.20117531>
26. Jerkovic I, Ljubic T, Basic Z, Krucic I, Kunac N, Bezic J, et al. SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County, Croatia [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.11.20095158>
27. Reifer J, Hayum N, Heszkel B, Klagsbald I, Streva VA. SARS-CoV-2 IgG antibody responses in New York City [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.23.20111427>
28. Emmenegger M, De Cecco E, Lamparter D, Jacquat RPB, Ebner D, Schneider MM, et al. Early plateau of SARS-CoV-2 seroprevalence identified by tripartite immunoassay in a large population [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.31.20118554>
29. Takita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, et al. Geographical profiles of COVID-19 outbreak in Tokyo: an analysis of the primary care clinic-based point-of-care antibody testing. *J Prim Care Community Health*. 2020 Jan-Dec;11:2150132720942695. doi: <http://dx.doi.org/10.1177/2150132720942695> PMID: 32674696
30. Crovetto F, Crispi F, Llorba E, Figueras F, Gomez-Roig MD, Gratacos E. Seroprevalence and clinical spectrum of SARS-CoV-2 infection in the first versus third trimester of pregnancy [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.06.17>
31. Fiore JR, Centra M, De Carlo A, Granato T, Rosa A, Sarno M, et al. Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. *J Med Virol*. 2020 Aug 13;jmv.26425. doi: <http://dx.doi.org/10.1002/jmv.26425> PMID: 32790086
32. Ling R, Yu Y, He J, Zhang J, Xu S, Sun R, et al. Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.06.16.20132423>
33. Chamie G, Marquez C, Crawford E, Peng J, Petersen M, Schwab D, et al. SARS-CoV-2 community transmission during shelter-in-place in San Francisco [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.06.15.20132233>
34. Gomes CC, Cerutti C, Zandonade E, Maciel EKN, Carvalho de Alencar FE, Almada GL, et al. A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.06.13.20130559>
35. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020. *JAMA Intern Med*. 2020 Jul 21. doi: <http://dx.doi.org/10.1001/jamainternmed.2020.4130> PMID: 32692365
36. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al.; ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet*. 2020 08 22;396(10250):535–44. doi: [http://dx.doi.org/10.1016/S0140-6736\(20\)31483-5](http://dx.doi.org/10.1016/S0140-6736(20)31483-5) PMID: 32645347
37. Feehan AK, Fort D, Garcia-Diaz J, Price-Haywood E, Velasco C, Sapp E, et al. Seroprevalence of SARS-CoV-2 and infection fatality ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. *Emerg Infect Dis*. 2020 Jul 30;26(11). doi: <http://dx.doi.org/10.3201/eid2611.203029> PMID: 32731911
38. Herzog S, De Bie J, Abrams S, Wouters I, Elkinci E, Patteet L, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium – a prospective cross sectional study of residual samples [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.06.08.20125179>
39. Fontanet A, Grant R, Tondeur L, Madec Y, Grzelak L, Cailleau I, et al. SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.06.25.20140178>
40. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. *Nat Med*. 2020 08;26(8):1193–5. doi: <http://dx.doi.org/10.1038/s41591-020-0949-6> PMID: 32504052
41. Amorim Filho L, Szwarcwald CL, Mateos SOG, Leon ACMP, Medronho RA, Veloso VG, et al.; Grupo Hemorio de Pesquisa em Covid-19. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil. *Rev Saude Publica*. 2020;54:69. PMID: 32638883
42. Tess BH, Granato CFH, Alves MC, Pintauro MC, Rizzatti E, Nunes MC, et al. SARS-CoV-2 seroprevalence in the municipality of São Paulo, Brazil, ten weeks after the first reported case [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/10.1101/2020.06.29.20142331>
43. Torres JP, Piñera C, De La Maza V, Lagomarcino AJ, Simian D, Torres B, et al. SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study. *Clin Infect Dis*. 2020 Jul 10;ciaa955. doi: <http://dx.doi.org/10.1093/cid/ciaa955> PMID: 32649743
44. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wankiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.27.20162693>
45. Nesbitt DJ, Jin D, Hogan JW, Chan PA, Simon MJ, Vargas M, et al. Low seroprevalence of SARS-CoV-2 in Rhode Island blood donors determined using multiple serological assay formats [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.20.20157743>
46. McLaughlin CC, Doll MK, Morrison KT, McLaughlin WL, O'Connor T, Sholukh AM, et al. High community SARS-CoV-2 antibody seroprevalence in a ski resort community, Blaine County, Idaho, US. preliminary results [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.19.20157198>

47. Figar S, Pagotto V, Luna L, Salto J, Manslau MW, Mistchenko AS, et al. Community-level SARS-CoV-2 seroprevalence survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.14.20153858>doi: <http://dx.doi.org/10.1101/2020.07.14.20153858>
48. Nawa N, Kuramochi J, Sonoda S, Yamaoka Y, Nukui Y, Miyazaki Y, et al. Seroprevalence of SARS-CoV-2 IgG antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.20.20155945>doi: <http://dx.doi.org/10.1101/2020.07.20.20155945>
49. Nisar I, Ansari N, Amin M, Khalid F, Hotwani A, Rehman N, et al. Serial population based serosurvey of antibodies to SARS-CoV-2 in a low and high transmission area of Karachi, Pakistan [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.28.20163451>doi: <http://dx.doi.org/10.1101/2020.07.28.20163451>
50. Skowronski DM, Sekirov I, Sabaiduc S, Zou M, Morshed M, Lawrence D, et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual serosurvey before and after first wave measures in British Columbia, Canada, March–May 2020 [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.13.20153148>doi: <http://dx.doi.org/10.1101/2020.07.13.20153148>
51. Abu Raddad LJ, Chemaitelly H, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.16.20155317>doi: <http://dx.doi.org/10.1101/2020.07.16.20155317>
52. Petersen MS, Strøm M, Christiansen DH, Fjallsbak JP, Eliassen EH, Johansen M, et al. Seroprevalence of SARS-CoV-2-specific antibodies, Faroe Islands. *Emerg Infect Dis.* 2020 Jul 29;26(11). doi: <http://dx.doi.org/10.3201/eid2611.202736> PMID: 32726200
53. Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al.; CDC Field Surveyor Team. Estimated community seroprevalence of SARS-CoV-2 antibodies - two Georgia counties, April 28–May 3, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Jul 24;69(29):965–70. doi: <http://dx.doi.org/10.15585/mmwr.mm6929e2> PMID: 32701941
54. Menachemi N, Yiannoutsos CT, Dixon BE, Duszynski TJ, Fadel WF, Wools-Kaloustian KK, et al. Population point prevalence of SARS-CoV-2 infection based on a statewide random sample - Indiana, April 25–29, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Jul 24;69(29):960–4. doi: <http://dx.doi.org/10.15585/mmwr.mm6929e1> PMID: 32701938
55. Chang L, Hou W, Zhao L, Zhang Y, Wang Y, Wu L, et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.13.20153106>doi: <http://dx.doi.org/10.1101/2020.07.13.20153106>
56. Meyers K, Liu L, Lin W-H, Luo Y, Yin M, Wu Y, et al. Antibody testing documents the silent spread of SARS-CoV-2 in New York prior to the first reported case [preprint]. Durham: Research Square; 2020. doi: <http://dx.doi.org/10.21203/rs.3.rs-39880/v1>
57. Merkely B, Szabó AJ, Kosztin A, Berényi E, Sebestyén A, Lengyel C, et al.; HUNGarian COronaVirus-19 Epidemiological Research (H-UNCOVER) investigators. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. *Geroscience.* 2020 Aug;42(4):1063–74. doi: <http://dx.doi.org/10.1007/s11357-020-00226-9> PMID: 32677025
58. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. *N Engl J Med.* 2020 Sep 1. *NEJMoa2026116* [online ahead of print]. doi: <http://dx.doi.org/10.1056/NEJMoa2026116> PMID: 32871063
59. Noh JY, Seo YB, Yoon JG, Seong H, Hyun H, Lee J, et al. Seroprevalence of anti-SARS-CoV-2 antibodies among outpatients in southwestern Seoul, Korea. *J Korean Med Sci.* 2020 Aug 24;35(33):e311. doi: <http://dx.doi.org/10.3346/jkms.2020.35.e311> PMID: 32830472
60. Xu R, Huang J, Duan C, Liao Q, Shan Z, Wang M, et al. Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou, China. *J Med Virol.* 2020 Aug 19. *jmv.26445*. [online ahead of print]. doi: <http://dx.doi.org/10.1002/jmv.26445> PMID: 32813273
61. Malani A, Shah D, Kang G, Lobo GN, Shastri J, Mohanan M, et al. Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29–July 19, 2020 [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.08.27.20182741>doi: <http://dx.doi.org/10.1101/2020.08.27.20182741>
62. Bogogiannidou Z, Vontas A, Dadouli K, Kyritsi MA, Soteriades S, Nikoulis DJ, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Euro Surveill.* 2020 Aug;25(31):2001369. doi: <http://dx.doi.org/10.2807/1560-7917.ES.2020.25.31.2001369> PMID: 32762796
63. Feehan AK, Velasco C, Fort D, Burton JH, Price-Haywood E, Katzmarzyk PT, et al. Racial and workplace disparities in seroprevalence of SARS-CoV-2 in Baton Rouge, Louisiana, 4 July 15–31, 2020 [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.08.26.20180968>doi: <http://dx.doi.org/10.1101/2020.08.26.20180968>
64. Westerhuis BM, de Bruin E, Chandler FD, Ramakers CRB, Okba NMA, Li W, et al. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.08.21.20177857>doi: <http://dx.doi.org/10.1101/2020.08.21.20177857>
65. Ward H, Atchinson C, Whitaker M, Ainslie KED, Elliott J, Okell L, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.08.12.20173690>doi: <http://dx.doi.org/10.1101/2020.08.12.20173690>
66. Javed W, Baqar J, Abidi SHB, Farooq W. Sero-prevalence findings from metropolises in Pakistan: implications for assessing COVID-19 prevalence and case-fatality within a dense, urban working population [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/10.1101/2020.08.13.20173914>doi: <http://dx.doi.org/10.1101/2020.08.13.20173914>
67. Khan MS, Qurieshi MA, Haq I, Majid S, Akbar A. Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – a cross-sectional study [preprint]. Cold Spring Harbor: bioRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.09.04.282640>doi: <http://dx.doi.org/10.1101/2020.09.04.282640>
68. Da Silva A, Lima-Neto L, de Azevedo C, da Costa L, Braganca M, Filho A, et al. Population-based seroprevalence of SARS-CoV-2 is more than halfway through the herd immunity threshold in the State of Maranhão, Brazil [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/10.1101/2020.08.28.20180463>doi: <http://dx.doi.org/10.1101/2020.08.28.20180463>
69. [Weekly report of the population serology survey of the corona epidemic.] Helsinki: Finland Department of Health and Welfare; 2020. [Finnish]. Available from: https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly.html [cited 2020 Jul 12].
70. [First results on antibodies after review of covid-19 in blood donors.] Solna: Swedish Public Health Agency; 2020. [Swedish]. Available from: <https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/juni/forsta-resultaten-om-antikroppar-efter-genomgangen-covid-19-hos-blodgivare/> [cited 2020 Jul 12].
71. [Studie SARS-CoV-2-CZ-Preval.] Prague: Institute of Health Information and Statistics of the Czech Republic; 2020. [Czech]. Available from: <https://covid-imunita.uzis.cz/res/file/prezentace/20200506-dusek.pdf> [cited 2020 Jul 12].
72. Jaffe-Hoffman M. Coronavirus herd immunity? Not in Israel, according to a serological study. *Jerusalem Post.* 2020 Jun 2. Available from: <https://www.jpost.com/israel-news/coronavirus-herd-immunity-not-in-israel-according-to-a-serological-study-630059> [cited 2020 Jul 12].
73. First study carried out on herd immunity of the population in the whole territory of Slovenia. Ljubljana: Republic of Slovenia; 2020. Available from: <https://www.gov.si/en/news/2020-05-06-first-study-carried-out-on-herd-immunity-of-the-population-in-the-whole-territory-of-slovenia/> [cited 2020 Jul 12].
74. [Popova declared immunity to coronavirus in 14% of those tested]. Interfax. 2020 Jun 10. [Russian]. Available from: <https://www.interfax.ru/russia/712617> [cited 2020 Aug 12].
75. Gul A. Ten million Afghans likely infected and recovered: COVID-19 survey. *VOA.* 2020 Aug 5. Available from: <https://www.voanews.com/south-central-asia/10-million-afghans-likely-infected-and-recovered-covid-19-survey> [cited 2020 Aug 12].
76. Preliminary results of seroprevalence study in Tbilisi: 10 out of 1068 residents have coronavirus antibodies. *Agenda.ge.* 2020 Jun 29. Available from: <https://agenda.ge/en/news/2020/2055> [cited 2020 Aug 12].
77. Genot L. In Brazil, COVID-19 hitting young people harder. *The Jakarta Post.* 2020 May 22. Available from: <https://www.thejakartapost.com/news/2020/05/22/in-brazil-covid-19-hitting-young-people-harder.html> [cited 2020 Jul 12].
78. COVID-19 pandemic in Croatia [internet]. Wikipedia; 2020. Available from https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Croatia [cited 2020 Jul 12].

79. COVID-19 coronavirus pandemic [internet]. Dover: Worldometer; 2020. Available from: <https://www.worldometers.info/coronavirus/> [cited 2020 Sep 12].
80. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. *Environ Res*. 2020 Sep;188:109890. doi: <http://dx.doi.org/10.1016/j.envres.2020.109890> PMID: 32846654
81. Booth R. Half of coronavirus deaths happen in care homes, data from EU suggests. *The Guardian*. 2020 Apr 13. Available from: <https://www.theguardian.com/world/2020/apr/13/half-of-coronavirus-deaths-happen-in-care-homes-data-from-eu-suggests> [cited 2020 Apr 27].
82. American Geriatrics Society. American Geriatrics Society Policy Brief: COVID-19 and nursing homes. *J Am Geriatr Soc*. 2020 May;68(5):908–11. doi: <http://dx.doi.org/10.1111/jgs.16477> PMID: 32267538
83. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020 Mar 17;323(11):1061–9. doi: <http://dx.doi.org/10.1001/jama.2020.1585> PMID: 32031570
84. Boccia S, Ricciardi W, Ioannidis JPA. What other countries can learn from Italy during the COVID-19 pandemic. *JAMA Intern Med*. 2020 Jul 1;180(7):927–8. doi: <http://dx.doi.org/10.1001/jamainternmed.2020.1447> PMID: 32259190
85. Brufsky A. Distinct viral clades of SARS-CoV-2: implications for modeling of viral spread. *J Med Virol*. 2020 Apr 20;92(9):1386–90. doi: <http://dx.doi.org/10.1002/jmv.25902> PMID: 32311094
86. Rosado J, Cockram C, Merklings SH, Demeret C, Meola A, Kerneis S, et al. Serological signatures of SARS-CoV-2 infection: implications for antibody-based diagnostics [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.07.20093963>doi: <http://dx.doi.org/10.1101/2020.05.07.20093963>
87. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020 Aug;26(8):1200–4. doi: <http://dx.doi.org/10.1038/s41591-020-0965-6> PMID: 32555424
88. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.03.30.20047365>doi: <http://dx.doi.org/10.1101/2020.03.30.20047365>
89. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.07.09.20148429>doi: <http://dx.doi.org/10.1101/2020.07.09.20148429>
90. Edouard S, Colson P, Melenotte C, De Pinto F, Thomas L, La Scola B, et al. Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.05.20092064>doi: <http://dx.doi.org/10.1101/2020.05.05.20092064>
91. Solbach W, Schiffner J, Backhaus I, Burger D, Staiger R, Tiemer B, et al. Antibody profiling of COVID-19 patients in an urban low-incidence region in northern Germany [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.30.20111393>doi: <http://dx.doi.org/10.1101/2020.05.30.20111393>
92. Ioannidis JPA. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. *Eur J Clin Invest*. 2020 Oct 7;e13421. doi: <http://dx.doi.org/10.1111/eci.13423> PMID: 33026101
93. Kikkert M. Innate immune evasion by human respiratory RNA viruses. *J Innate Immun*. 2020;12(1):4–20. doi: <http://dx.doi.org/10.1159/000503030> PMID: 31610541
94. Krammer F. The human antibody response to influenza A virus infection and vaccination. *Nat Rev Immunol*. 2019 Jun;19(6):383–97. doi: <http://dx.doi.org/10.1038/s41577-019-0143-6> PMID: 30837674
95. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19 [preprint]. Cold Spring Harbor: bioRxiv. 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.05.21.108308>doi: <http://dx.doi.org/10.1101/2020.05.21.108308>
96. Gallais F, Velay A, Wendling M-J, Nazon C, Partisani M, Sibilia J, et al. Intrafamilial exposure to SARS-CoV-2 induces cellular immune response without seroconversion [preprint]. Cold Spring Harbor: medRxiv; 2020. doi: <http://dx.doi.org/https://doi.org/10.1101/2020.06.21.20132449>doi: <http://dx.doi.org/10.1101/2020.06.21.20132449>
97. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin J-B, Olsson A, et al.; Karolinska COVID-19 Study Group. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell*. 2020 10 1;183(1):158–168.e14. doi: <http://dx.doi.org/10.1016/j.cell.2020.08.017> PMID: 32979941

Table 1. Eligible seroprevalence studies on COVID-19 published or deposited as preprints as of 9 September 2020: dates, sampling and recruitment

Author	Country (location)	Dates	Sampling and recruitment
Figar et al. ⁴⁷	Argentina (Barrio Padre Mugica)	10–26 June	Probabilistic sampling of a slum neighbourhood, sampling from people 14 years or older across households
Herzog et al. ³⁸	Belgium	30 March–5 April and 20–26 April	Residual sera from 10 private diagnostic laboratories in Belgium, with fixed numbers per age group, region and periodical sampling, and stratified by sex
Hallal et al. ²⁵	Brazil	15–22 May	Sampling from 133 cities (the main city in each region), selecting 25 census tracts with probability proportionate to size in each sentinel city, and 10 households at random in each tract. Aiming for 250 participants per city
Gomes et al. ³⁴	Brazil (Espírito Santo)	13–15 May	Cross-section of major municipalities with houses as the sampling units
Da Silva et al. ⁶⁸	Brazil (Maranhao)	27 July–8 August	Three-stage cluster sampling stratified by four state regions in the state of Maranhao; the estimates took clustering, stratification and non-response into account
Amorim Filho et al. ⁴¹	Brazil (Rio de Janeiro)	14–27 April (eligible: 24–27 April)	Blood donors without flulike symptoms within 30 days of donation; had close contact with suspected or confirmed COVID-19 cases in the 30 days before donation; or had travelled abroad in the past 30 days
Silveira et al. ¹⁷	Brazil (Rio Grande do Sul)	9–11 May (third round, after 11–13 April, and 25–27 April)	Multistage probability sampling in each of nine cities to select 500 households, from which one member was randomly chosen for testing
Tess et al. ⁴²	Brazil (Sao Paulo)	4–12 May	Randomly selected adults and their cohabitants sampled from six districts of Sao Paulo City with high numbers of cases
Skowronski et al. ⁵⁰	Canada (British Columbia)	15–27 May (after baseline in 5–13 March)	Specimens from patients attending one of about 80 diagnostic service centres of the only outpatient laboratory network in the Lower Mainland
Torres et al. ⁴³	Chile (Vitacura)	4–19 May	Classroom stratified sample of children and all staff in a community placed on quarantine after school outbreak
Chang et al. ⁵⁵	China	January–April weekly: 3–23 February (Wuhan); 24 February–15 March (Shenzhen); 10 February–1 March (Shijiazhuang)	38 144 healthy blood donors in Wuhan, Shenzhen and Shijiazhuang who met the criteria for blood donation during the COVID-19 pandemic in China
Wu et al. ¹⁴	China (Wuhan)	3–15 April	People applying for permission to resume work ($n = 1021$) and hospitalized patients ($n = 381$)
Ling et al. ³²	China (Wuhan)	26 March–28 April	Age 16–64 years, going back to work, with no fever, headache or other symptoms of COVID-19
Xu et al. ⁶⁰	China (Guangzhou)	23 March–2 April	Healthy blood donors in Guangzhou
Xu et al. ⁴⁰	China (several regions)	30 March–10 April	Voluntary participation by public call for haemodialysis patients ($n = 979$ in Jingzhou, Hubei and $n = 563$ in Guangzhou/Foshan, Guangdong) and outpatients in Chongqing ($n = 993$), and community residents in Chengdu, Sichuan ($n = 9442$), and required testing for factory workers in Guangzhou, Guangdong ($n = 442$)
Jerkovic et al. ²⁶	Croatia	23–28 April	DIV Group factory workers in Split and Sibenik-Knin invited for voluntary testing
Erikstrup et al. ¹²	Denmark	6 April–3 May	All Danish blood donors aged 17–69 years giving blood. Blood donors are healthy and must comply with strict eligibility criteria; they must self-defer for two weeks if they develop fever with upper respiratory symptoms
Petersen et al. ⁵²	Denmark (Faroe Islands)	27 April–1 May	1 500 randomly selected residents invited to participate, samples collected from 1075
Fontanet et al. ³⁹	France (Crepny-en-Valois)	28–30 April	Pupils, their parents and relatives, and staff of primary schools exposed to SARS-CoV-2 in February and March 2020 in a city north of Paris
Fontanet et al. ¹³	France (Oise)	30 March–4 April	Pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school
Streeck et al. ¹⁶	Germany (Gangelt)	30 March–6 April	600 adults with different surnames in Gangelt were randomly selected; all household members were asked to participate in the study

(continues. . .)

(. . .continued)

Author	Country (location)	Dates	Sampling and recruitment
Kraehling et al. ²¹	Germany (Frankfurt)	6–14 April	Employees of Infraseriv Höchst, a large industrial site operator in Frankfurt am Main. No exclusion criteria
Bogogiannidou et al. ⁶²	Greece	March and April (April data used)	Leftover blood samples collected from a nationwide laboratory network, including both private and public hospital laboratories (27 laboratories in total)
Merkely et al. ⁵⁷	Hungary	1–16 May	Representative sample ($n = 17\,787$) of the Hungarian population ≥ 14 years living in private households (8 283 810)
Gudbjartsson et al. ⁵⁸	Iceland	Several cohorts between April and June ^a	30 576 people in Iceland, including those documented to be infected, those quarantined and people not known to have been exposed
Malani et al. ⁶¹	India (Mumbai)	29 June–19 July	Geographically-spaced community sampling of households, one individual per household was tested in slum and non-slum communities in three wards, one each from the three main zones of Mumbai
Khan et al. ⁶⁷	India (Srinagar)	1–15 July	Adults (> 18 years) who visited selected hospitals across the Srinagar District
Shakiba et al. ⁸	Islamic Republic of Iran (Guilan)	April (until 21 April)	Population-based cluster random sampling design through telephone call invitation, household-based
Fiore et al. ³¹	Italy (Apulia)	1–31 May	Blood donors 18–65 years old free of recent symptoms possibly related to COVID-19, no close contact with confirmed cases, symptom-free in the preceding 14 days, no contact with suspected cases
Doi et al. ¹¹	Japan (Kobe)	31 March–7 April	Randomly selected patients who visited outpatient clinics and received blood testing for any reason. Patients who visited the emergency department or the designated fever consultation service were excluded
Takita et al. ²⁹	Japan (Tokyo)	21 April–20 May	Two community clinics in the main railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa)
Nawa et al. ⁴⁸	Japan (Utsunomiya City)	14 June–5 July	Invitations enclosed with a questionnaire were sent to 2290 people in 1 000 households randomly selected from Utsunomiya City's basic resident registry; 742 completed the study
Uyoga et al. ⁴⁴	Kenya	30 April–16 June (~90% of samples in last 30 days)	Residual blood donor serum samples from donors 16–65 years in four sites (Mombasa, Nairobi, Eldoret and Kisumu)
Snoeck et al. ²⁰	Luxembourg	16 April–5 May	Representative sample (no details how ensured), 1807 of 2000 contacted provided data, were < 79 years and had serology results
Slot et al. ¹⁵	Netherlands	1–15 April	Blood donors. Donors must be completely healthy, but they may have been ill in the past, provided that they recovered at least 2 weeks before
Westerhuis et al. ⁶⁴	Netherlands (Rotterdam)	Early March and early April	Left-over plasma samples from patients of nine age categories in Erasmus Medical Center in Rotterdam: 879 samples in early March and 729 in early April)
Nisar et al. ⁴⁹	Pakistan (Karachi)	25 June–11 July (after baseline on 15–25 April)	Cross-sectional household surveys in a low- (district Malir) and high-transmission (district East) area of Karachi with households selected using simple random sampling (Malir) and systematic random sampling (East)
Javed et al. ⁶⁶	Pakistan (urban Karachi, Lahore, Multan, Peshawar and Quetta)	Up to 6 July	Adult, working population aged 18–65 years, recruited from dense, urban workplaces including factories, businesses, restaurants, media houses, schools, banks, hospitals (health-care providers), and from families of positive cases in cities in Pakistan
Abu Raddad et al. ⁵¹	Qatar	12 May–12 July (highest seroprevalence on 12–31 May)	Convenience sample of residual blood specimens collected for routine clinical screening or clinical management from 32 970 outpatient and inpatient departments for a variety of health conditions ($n = 937$ in 12–31 May)
Noh et al. ⁵⁹	Republic of Korea	25–29 May	Outpatients who visited two hospitals in south-west Seoul which serve six administrative areas
Pollán et al. ³⁶	Spain	27 April–11 May	35 883 households selected from municipal rolls using two-stage random sampling stratified by province and municipality size, with all residents invited to participate (75.1% of all contacted individuals participated)

(continues. . .)

(. . .continued)

Author	Country (location)	Dates	Sampling and recruitment
Crovetto et al. ³⁰	Spain (Barcelona)	14 April–5 May	Consecutive pregnant women for first trimester screening or delivery in two hospitals
Stringhini et al. ¹⁰	Switzerland (Geneva)	6 April–9 May (5 consecutive weeks)	Randomly selected previous participants of the Bus Santé study with an email (or telephone contact, if email unavailable); participants were invited to bring all members of their household aged 5 years and older
Emmenegger et al. ²⁸	Switzerland (Zurich)	Prepandemic until June (patients) and May (blood donors)	Patients at the University Hospital of Zurich and blood donors in Zurich and Lucerne
Ward et al. ⁶⁵	United Kingdom (England)	20 June–13 July	Random population sample of 100 000 adults over 18 years
Thompson et al. ¹⁸	United Kingdom (Scotland)	21–23 March	Blood donors. Donors should not have felt unwell in the past 14 days; some other deferrals also applied regarding travel and COVID-19 symptoms
Havers et al. ³⁵	USA (10 states)	23 March–1 April (Washington, Puget Sound and New York, New York City), 1–8 April (Louisiana), 5–10 April (Florida, south), 13–25 April (Pennsylvania, Philadelphia, metropolitan area), 20–26 April (Missouri), 23–27 April (California, San Francisco Bay Area), 20 April–3 May (Utah), 26 April–3 May (Connecticut), 30 April–12 May (Minnesota, Minneapolis)	Convenience samples using residual sera obtained for routine clinical testing (screening or management) by two commercial laboratory companies
Ng et al. ²⁴	USA (California, Bay Area)	March	1000 blood donors in diverse Bay Area locations (excluding those with self-reported symptoms or abnormal vital signs)
Sood ²²	USA (California, Los Angeles)	10–14 April	Proprietary database representative of the county. A random sample of these residents was invited, with quotas for enrolment for subgroups based on age, sex, race and ethnicity distribution
Chamie et al. ³³	USA (California, San Francisco)	25–28 April	United States census tract 022 901 population-dense area (58% Latin American) in San Francisco Mission district, expanded to neighbouring blocks on 28 April
Bendavid et al. ¹⁹	USA (California, Santa Clara)	2–3 April	Facebook advertisement with additional targeting by zip code
Biggs et al. ⁵³	USA (Georgia, DeKalb and Fulton)	28 April–3 May	Two-stage cluster sampling design used to randomly select 30 census blocks in DeKalb County and 30 census blocks in Fulton County, with a target of seven participating households per census block
McLaughlin et al. ⁴⁶	USA (Idaho, Blaine County)	4–19 May	Volunteers who registered via a secure web link, using prestratification weighting to the population distribution by age and sex within each zip code
Bryan et al. ⁹	USA (Idaho, Boise)	Late April	People from the Boise, Idaho metropolitan area, part of the Crush the Curve initiative
Menachemi et al. ⁵⁴	USA (Indiana)	25–29 April	Stratified random sampling among all persons aged ≥ 12 years using Indiana's 10 public health preparedness districts as sampling strata
Feehan et al. ⁶³	USA (Louisiana, Baton Rouge)	15–31 July	Representative sample in a method developed by Public Democracy
Feehan et al. ³⁷	USA (Louisiana, Orleans and Jefferson Parish)	9–15 May	Pool of potential participants reflecting the demographics of the parishes was based on 50 characteristics, then a randomized subset of 150 000 people was selected, and 25 000 were approached with digital apps, and 2640 were recruited

(continues. . .)

(. . .continued)

Author	Country (location)	Dates	Sampling and recruitment
Rosenberg et al. ²³	USA (New York)	19–28 April	Convenience sample of people ≥ 18 years living in New York State, recruited consecutively on entering 99 grocery stores and through an in-store flyer
Meyers et al. ⁵⁶	USA (New York)	2–30 March (Columbia University Medical Center, New York City); 13–28 March (CareMount central laboratory)	Discarded clinical samples in Columbia Medical Center, New York City (<i>n</i> = 814 in 24 February–30 March, 742 of those in the period 2–30 March) and samples from CareMount central laboratory (960 samples on 13/14 March, 505 samples on 20/21 March, and 376 samples on 27/28 March) from its network of clinics in five counties north of New York City
Reifer et al. ²⁷	USA (New York, Brooklyn)	Early May	Patients seen in an urgent care facility in Brooklyn
Nesbitt et al. ⁴⁵	USA (Rhode Island)	27 April–11 May	Consecutive blood donors

COVID-19: coronavirus disease 19; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

^a Sample collection time for some sub-cohorts may have exceeded 1 month, but more than half of the cases were already documented by polymerase chain reaction testing before any antibody testing and the last death occurred on 20 April.

Note: Some studies included additional data sets that did not fulfil the eligibility criteria (e.g. had sample size < 500 or were health-care workers) and they are not presented here.

Table 2. Sample size, types of antibodies assessed and population size in the studies included to assess COVID-19 infection fatality rate, 2020

Country (location)	Sample size ^a , no.	Antibody	Population, ^{b,c,d} no.	% of population < 70 years ^c
Argentina (Barrio Padre Mugica) ⁴⁷	873	IgG	49 983	99
Belgium ³⁸	3 391 (20–26 April)	IgG	11 589 623	86
Brazil (133 cities) ²⁵	24 995	IgG and IgM	74 656 499	94 (Brazil)
Brazil (Espírito Santo) ³⁴	4 608	IgG and IgM	4 018 650	94 (Brazil)
Brazil (Maranhão) ⁶⁸	3 156	IgG and IgM	7 114 598	92
Brazil (Rio de Janeiro), blood donors ⁴¹	669 (24–27 April)	IgG and IgM	17 264 943	94 (Brazil)
Brazil (Rio Grande do Sul) ¹⁷	4 500	IgG	11 377 239	91
Brazil (Sao Paulo) ⁴²	517	IgG and IgM	298 240 (6 districts)	94 (Brazil)
Canada (British Columbia) ⁵⁰	885	IgG, IgM and IgA	5 071 000	94
Chile (Vitacura) ⁴³	1 244	IgG and IgM	85 000	92 (Chile)
China, blood donors ⁵⁵				
Wuhan	930 (3–23 February)	IgG and IgM	11 210 000	93 (China)
Shenzhen	3 507 (24 February–15 March)	IgG and IgM	13 030 000	93 (China)
Shijiazhuang	6 455 (10 February–1 March)	IgG and IgM	11 030 000	93 (China)
China (Wuhan) ¹⁴	1 401	IgG and IgM	11 080 000	93 (China)
China (Wuhan) ³²	1 196 (4–8 April)	IgG and IgM	11 080 000	93 (China)
China (Guangzhou), blood donors ⁶⁰	2 199	IgG, IgM and IgA	115 210 000 (Guangdong)	93 (China)
China (several regions) ⁴⁰				
Hubei (not Wuhan)	979	IgG and IgM	48 058 000	93 (China)
Chongqing	993	IgG and IgM	31 243 200	93 (China)
Sichuan	9 442	IgG and IgM	83 750 000	93 (China)
Guangdong	1 005	IgG and IgM	115 210 000	93 (China)
Croatia ²⁶	1 494	IgG and IgM	4 076 000	86
Denmark blood donors ¹²	20 640	IgG and IgM	5 771 876	86
Denmark (Faroe Islands) ⁵²	1 075	IgG and IgM	52 428	88
France (Crepy-en-Valois) ³⁹	1 340	IgG	5 978 000 (Hauts-de-France)	89
France (Oise) ¹³	661	IgG	5 978 000 (Hauts-de-France)	89
Germany (Gangelt) ¹⁶	919	IgG and IgA	12 597	86
Germany (Frankfurt) ²¹	1 000	IgG	2 681 000 ^e	84 (Germany)
Greece ⁶²	6 586 (4 511 in April)	IgG	10 412 967	84
Hungary ⁵⁷	10 504	IgG (also had RT-PCR)	9 657 451	88
Iceland ⁵⁸	30 576	Pan-Ig	366 854	90
India (Mumbai) ⁶¹	6 904 (4 202 in slums, 2 702 not in slums)	IgG	1 414 917 (705 523 in slums, 709 394 in non-slums) in the 3 ward areas	98
India (Srinagar) ⁶⁷	2 906	IgG	1 500 000	97
Islamic Republic of Iran (Guilan) ⁸	551	IgG and IgM	2 354 848	95
Italy (Apulia), blood donors ³¹	909	IgG and IgM	4 029 000	84
Japan (Kobe) ¹¹	1 000	IgG	1 518 870	79 (Japan)
Japan (Tokyo) ²⁹	1 071	IgG	13 902 077	79 (Japan)
Japan (Utsunomiya City) ⁴⁸	742	IgG	518 610	79 (Japan)
Kenya, blood donors ⁴⁴	3 098	IgG	47 564 296	99
Luxembourg ²⁰	1 807	IgG and IgA ^f	615 729	90
Netherlands blood donors ¹⁵	7 361	IgG, IgM and IgA	17 097 123	86
Netherlands (Rotterdam) ⁵⁴	729 (early April)	IgG	17 097 123 (Netherlands)	86
Pakistan (Karachi) ⁴⁹	1 004	IgG and IgM	16 700 000	98 (Pakistan)
Pakistan (urban) ⁶⁶	24 210	IgG and IgM	79 000 000 (urban)	98
Qatar ⁵¹	937	IgG	2 800 000	99
Republic of Korea ⁵⁹	1 500	IgG	2 667 341	90 (Republic of Korea)
Spain ³⁶	61 075	IgG	46 940 000	85
Spain (Barcelona) ³⁰	874	IgG, IgM and IgA	7 566 000 (Catalonia)	86
Switzerland (Geneva) ¹⁰	577 (20–27 April)	IgG	500 000	88

(continues...)

(. . .continued)

Country (location)	Sample size ^a , no.	Antibody	Population, ^{b,c,d} no.	% of population < 70 years ^c
Switzerland (Zurich) ²⁸	1 644 patients (1–15 April)	IgG	1 520 968 (Zurich canton)	88
Switzerland (Zurich and Lucerne) ²⁸	1 640 blood donors (May)	IgG	1 930 525 (Zurich and Lucerne)	88
United Kingdom (England) ⁵⁵	109 076	IgG	56 287 000	86
United Kingdom (Scotland), blood donors ¹⁸	500	IgG	5 400 000	88
USA (10 states) ³⁵				
Washington, Puget Sound	3 264	Pan-Ig	4 273 548	90 (Washington)
Utah	1 132	Pan-Ig	3 282 120	92
New York, New York City	2 482	Pan-Ig	9 260 870	89
Missouri	1 882	Pan-Ig	6 110 800	88
Florida, south	1 742	Pan-Ig	6 345 345	86 (Florida)
Connecticut	1 431	Pan-Ig	3 562 989	88
Louisiana	1 184	Pan-Ig	4 644 049	92
California, San Francisco Bay	1 224	Pan-Ig	2 173 082	90
Pennsylvania, Philadelphia	824	Pan-Ig	4 910 139	90
Minnesota, Minneapolis	860	Pan-Ig	3 857 479	90
USA (California, Bay Area) ²⁴	1 000	IgG	7 753 000	90
USA (California, Los Angeles) ²²	863	IgG and IgM	7 892 000	92
USA (California, San Francisco) ³³	3 953	IgG and RT-PCR	5 174 (in census tract 022 901)	95
USA (California, Santa Clara) ¹⁹	3 300	IgG and IgM	1 928 000	90
USA (Idaho, Boise) ⁹	4 856	IgG	481 587 (Ada County)	92
USA (Georgia, DeKalb and Fulton Counties) ⁵³	696	Total Ig	1 806 672	88 (Georgia)
USA (Idaho, Blaine County) ⁴⁶	917	IgG	23 089	92
USA (Indiana) ⁵⁴	3 629	IgG and RT-PCR	6 730 000	89
USA (Louisiana, Baton Rouge) ⁶³	138	IgG	699 200 (East Baton Rouge, West Baton Rouge, Ascension, Livingston)	92 (Louisiana)
USA (Louisiana, Orleans and Jefferson Parish) ³⁷	2 640	IgG	825 057	92 (Louisiana)
USA (New York) ²³	15 101	IgG	19 450 000	90
USA, New York ⁵⁶				
Columbia University Medical Center, New York City	742 (2–30 March)	IgG and IgM	9 260 870	89
CareMount central laboratory, five New York state counties	1 841	IgG and IgM	10 189 130 (New York state excluding New York City)	89
USA (New York, Brooklyn) ²⁷	11 092	IgG	2 559 903	91
USA (Rhode Island), blood donors ⁴⁵	1 996	IgG and IgM	1 059 000	88

COVID-19: coronavirus disease 19; Ig: immunoglobulin; RT-PCR: real-time polymerase chain reaction.

^a Dates in brackets are the specific dates used when seroprevalence was evaluated at multiple consecutive time points or settings.

^b Some studies focused on age-restricted populations of the specific location under study, for example: people 17–70 years in the Denmark blood donor study ($n = 3\,800\,000$); people 18–79 years in the Luxembourg study ($n = 483\,000$); people < 70 years in the Netherlands blood donor study ($n = 13\,745\,768$); people ≥ 18 years in the New York state study ($n = 15\,280\,000$); people > 19 years in the Utah population of the 10-state United States of America study ($n = 2\,173\,082$); people ≥ 18 years in Blaine County, Idaho ($n = 17\,611$); people 15–64 years in the Kenya blood donor study ($n = 27\,150\,165$); people > 14 years living in private premises in Hungary ($n = 8\,283\,810$); people > 18 years ($n = 551\,185$) in Baton Rouge, Louisiana; people 18–65 years working in urban locations in Pakistan ($n = 22\,100\,000$); and people > 18 years in Srinagar District, India ($n = 1\,020\,000$). In this table and subsequent analyses, the entire population in the location is considered for consistency across studies.

^c Information in parentheses specifies the population.

^d When the population of the relevant location was not given in a specific study, information on recent estimates of the pertinent population was obtained by standard online sources such as: populationpyramid.net, worldpopulationreview.com, worldometers.info/coronavirus, and Wikipedia.

^e Participants were recruited from a large number of districts, but most districts had very few participants; here I included the population of the nine districts with > 1:10 000 sampling ratio (846/1000 participants came from these nine districts).

^f Considered positive if both IgG and IgA were positive; in the other studies, detection of any antibody was considered positive.